Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (466)	1/28/2001 1:58:11 PM
From: Mike McFarland	Respond to of 1833

Heh, my minimal effort wont get you to the bottom line, but you're welcome. I've no idea how royalties might flow from Solvay to Cadus. CDS-096370 is listed somewhere on the thread, but since OSI isn't working with Solvay on that anymore who knows? Very confusing to me too. As you know, I use the Keep It Simple Stupid system of investing--but you can be sure when KDUS dropped to 5/8ths, I was scratching my head, dumbfounded--all I know is that this thing is trading for less than cash. Eventually some smart company will come around a grab what OSI didn't steal at the garage sale. That gets you 2 or 3x (??) maybe better--or perhaps you fall into some nifty little startup that isn't a goofy shell that everybody is afraid to own. Same old stuff, nothing new, but nifty website: thelabrat.com G-protein coupled receptors - Several adenosine receptor compounds are under development by OSI. Promising adenosine A1 and adenosine A2B receptor targeted compounds will undergo evaluation as candidates for asthma. The A1 compound is targeted for the treatment of the bronchoconstriction associated with the acute phase of an asthma attack while the A2B compound is directed toward blocking the inflammatory components produced by mast cells and associated with the longer-term damage caused by the disease. OSI also has potent and selective A2A targeted compounds that have potential for development as both anti-angiogenesis agents and for the treatment of Parkinson's disease. Additionally, OSI has a selective adenosine A3 targeted compound that is undergoing extensive evaluation in animal models for glaucoma. In addition, an A1 targeted compound, CDS-096370, has potential for use in the treatment of congestive heart failure and renal failure. _______________________________ ...yikes. Uh, let us not use the F word too much around here. If Icahn/Glass have any interest in this, Cadus shares will evolve into something that could send my kiddo to Harvard: She sits on my lap and watches Daddy type, but wont be reading for awhile...thank goodness!